ERBB2 Rabbit Polyclonal Antibody

CAT#: TA366789

ERBB2 rabbit polyclonal antibody

Product Images

Gel: 6%SDS-PAGE Lysate: 40 μg Lane: Mouse brain tissue lysate Primary antibody: TA366789 (ERBB2 Antibody) at dilution 1/650 Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution Exposure time: 1 minute

• 

  Immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using TA366789 (ERBB2 Antibody) at dilution 1/60 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using TA366789 (ERBB2 Antibody) at dilution 1/60, treated with synthetic peptide. (Original magnification: ×200)

Specifications

Product Data

• Applications: IHC, WB
• Recommended Dilution: WB: 500-2000
  WB positive control: Mouse brain tissue lysate
  IHC: 50-100
  Positive control: Human colorectal cancer
  Predicted cell location: Cytoplasm
• Reactivities: Human, Mouse
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: Synthetic peptide of human ERBB2
• Formulation: pH7.4 PBS, 0.05% NaN3, 40% Glycerol
• Concentration: lot specific
• Purification: Antigen affinity purification
• Conjugation: Unconjugated
• Storage: Store at -20°C.
• Stability: 1 year
• Predicted Protein Size: 138 kDa
• Database Link:
  UniProt ID P04626
• Background: This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.